SCHEMBL31161864

SCHEMBL31161864

COC(=O)c1cnc(OC)c(NCCC(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.45
▸ ALDH1A1 P00352 7/20 0.44
▸ KDM4E B2RXH2 7/20 0.41
▸ HSD17B10 Q99714 4/20 0.41
▸ HPGD P15428 3/20 0.41
▸ MAPK1 P28482 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ATM Q13315 1/20 0.38
▸ MAPT P10636 2/20 0.36
▸ APEX1 P27695 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ AKR1C2 P52895 1/20 0.36
▸ AKR1C1 Q04828 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ PSMD14 O00487 1/20 0.36
▸ EHMT2 Q96KQ7 1/20 0.36
▸ EHMT1 Q9H9B1 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25031090 0.75 POLB (0.60) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL31161532 0.75 CYP2C9 (0.47) POLBTDP1ALDH1A1KDM4EL3MBTL1
SCHEMBL31161183 0.73 POLB (0.61) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL31161643 0.73 POLB (0.54) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL25935487 0.72 POLB (0.60) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL24670733 0.72 POLB (0.64) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL23121876 0.72 TDP1 (0.68) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL29720831 0.72 TDP1 (0.68) POLBTDP1ALDH1A1KDM4EHSD17B10
SCHEMBL24934082 0.72 MAPK1 (0.45) POLBTDP1ALDH1A1KDM4EHPGD
SCHEMBL4390565 0.71 ATM (0.51) POLBTDP1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 POLB 560/4885TDP1 1302/4885ALDH1A1 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback